

RESEARCH

Open Access

Circulating LH/hCG receptor (LHCGR) may identify pre-treatment IVF patients at risk of OHSS and poor implantation

Anne E Chambers^{1,3}, Krishnaveni P Nayini², Walter E Mills³, Gillian M Lockwood² and Subhasis Banerjee^{1,3*}

Abstract

Background: Successful pregnancy via *in vitro* fertilization (IVF) depends on the recovery of an adequate number of healthy oocytes and on blastocyst implantation following uterine transfer. Two hormones, LH and hCG, utilize a common LH/hCG receptor (LHCGR), variations in which have profound implications in human reproduction. Soluble LHCGR (sLHCGR) is released from experimental cell lines and placental explants and it can be detected in the follicular fluid and serum.

Methods: To evaluate the impact of circulating soluble LHCGR (sLHCGR) in fertility treatment, we measured sLHCGR and LH-sLHCGR complex in serum from women seeking IVF using specifically developed quantitative enzyme-linked immunosorbent assays (ELISA). Following an IVF cycle of treatment, patients were grouped according to oocyte yield into low (lower than or equal to 7 oocytes), intermediate (8-14 oocytes) and high (greater than or equal to 15 oocytes) responders and pregnancy outcome noted.

Results: Pre-treatment sLHCGR identified many women at risk of ovarian hyperstimulation. Low levels of sLHCGR were associated with pregnancy in both high and low responders but sLHCGR did not significantly affect the treatment outcome of intermediate responders. Low responders who failed to become pregnant had high levels of circulating sLHCGR bound to LH (LH-sLHCGR).

Conclusions: Pre-treatment measurement of sLHCGR could be used to tailor individual fertility treatment programs and improve outcomes by avoiding ovarian hyperstimulation and poor embryo implantation.

Keywords: soluble LHCGR, LH-LHCGR, AMH, FSH, OHSS, IVF, Pregnancy

Background

Given that about three-quarters of human embryos created by assisted reproductive technology (ART) such as IVF and ICSI fail to produce live births following uterine transfer [1], there has been increasing interest in identifying pre-treatment factors that may indicate the likelihood of success with fertility treatments. The follicle stimulating hormone [FSH] and luteinizing hormone [LH], play central roles in the maturation of the ovarian follicles and ovulation. Following ovulation, the remaining cells of the follicle are luteinized by LH and secrete progesterone plus oestradiol which are necessary for implantation of the

embryo [2]. One of the important aspects of the female reproductive cycle is that ovulation is controlled by a pulsatile secretion of LH (LH surge) that is subject to individual variation [3]. In controlled ovarian stimulation (COS), this variability of ovarian activities is temporarily eliminated by GnRH agonists/antagonists, while at the same time the ovarian functions are regulated by exogenously injected FSH and LH/hCG [4-7].

In addition to routine estimation of LH and FSH, the serum concentrations of anti-mullerian hormone (AMH) are often measured prior to COS. While LH or FSH alone or together provide a measure of the ovarian activity, AMH is the reliable marker for functional ovarian reserve [8]. Moreover, high AMH levels (> 45 pmol/L) are indicative of polycystic ovary (PCO) and these patients are usually susceptible to ovarian hyperstimulation syndrome

* Correspondence: dr_sbenerjee@hotmail.com

¹Department of Clinical Biochemistry, Heartlands Hospital, Birmingham B9 5SS, UK

Full list of author information is available at the end of the article

(OHSS) following hormonal induction. The serum AMH concentrations, being independent of the phase of the reproductive cycle, also appear to have some predictive value with respect to the pregnancy outcome [9,10].

The receptors expressed on the surface of target cells for LH and human chorionic gonadotrophin (hCG) binding and signalling are identical and are therefore described as the LH/hCG receptor or LHCGR [11]. In addition to ovary and testis, various isoforms of LHCGR are expressed almost ubiquitously in primary and secondary reproductive organs (uterus, fallopian tube, placenta and breast) and in a variety of extragonadal tissues including vascular endothelial and smooth muscle cells, brain, lymphocytes, macrophages, skin as well as foetal tissues [12,13]. The physiological significance of the extragonadal expression of LHCGR remains unexplained.

The earliest experimental evidence of the cell-free existence of LH receptor was its hCG-affinity purification from porcine follicular fluid [14]. The detection of a M_r 80-90K LH-LH receptor complex from Leydig cell culture media [15] and a M_r 30-60K LH-receptor binding protein in serum from uremic boys suffering from hypogonadism provided further clues to the extracellular appearance of soluble LH receptor. Notably, both soluble LH receptor and the hCG-receptor complexes have been shown to be released from cells transfected with cloned LH receptor [16-18]. However, the clinical significance of the cell-free soluble LHCGR remained unknown due to the lack of a convenient experimental system for quantitative estimation of the soluble receptor in body fluids.

We have recently shown that soluble LH/hCG receptor (sLHCGR) is released from LHCGR-transfected cells, placental explants [19] and into the bloodstream of pregnant women. Here, we describe the development and use of quantitative ELISA assays for the measurement of sLHCGR and hormone-receptor complex (LH-sLHCGR) in the serum of women presenting for IVF treatment. The assays described detect the analytes in follicular fluid, serum and plasma samples from the same patient. Our results demonstrate that women with high pre-treatment serum sLHCGR or LH-sLHCGR are usually low responders, produce reduced number of oocytes (≤ 5 oocytes) and are less likely to become pregnant. In addition, low to undetectable pre-treatment circulating LHCGR/LH-receptor complex is associated with high ovarian response (≥ 15 oocytes) and OHSS. The clinical applications of these assays in predicting ovarian response to fertility treatment and improving implantation potential following embryo transfer are discussed.

Methods

Antibodies

Purified LHR29 monoclonal antibody [19,20] was initially provided by Dr Hugues Loosfelt (INSERM, France) and

subsequently the antibody producing clone was obtained from ATCC (Clone ID CRL-2685). The epitope for the LHR29 monoclonal antibody was mapped using LHCGR recombinant proteins expressed in CHO cells [19]. It resides within amino acid residues 229 to 291 of the N-terminus extracellular domain (ECD) of LHCGR. A 19 amino acid residue LHCGR peptide (LHCGR 209-227; Swissprot: locus LSHR_HUMAN, accession P22888) was used to produce a second monoclonal antibody, clone 5A10C9. This antibody was purified from culture supernatant by Protein A affinity chromatography. The monoclonal antibody against luteinizing hormone β (LH β) clone 2LH2-L1 was obtained from HyTest Ltd. (Turku, Finland). In addition to this, a variety of polyclonal antibodies against LHCGR and monoclonal antibodies against LH β were tested during assay development. Antibodies were conjugated to Horse Radish Peroxidase using a Lightning-Link HRP conjugation kit according to the manufacturer's instructions (Innova Biosciences, Cambridge, UK). Briefly, 10 μ L of LL-modifier was added to 100 μ g (100 μ L) of affinity purified antibody and was conjugated either for three hours or overnight before the reaction was stopped using 10 μ L of LL-Quencher reagent for 30 minutes. Conjugated antibodies were stabilized by the addition of 10 μ L Peroxidase Stabilizer (Cosmo Bio Co. Ltd., Japan) and stored at 4°C for up to six months. The specificity of the assay was established by a variety of controls including mock/LHCGR ECD-expressing Chinese Hamster Ovary (CHO) cell extracts and isotype-specific IgGs from rabbit, mouse and goat.

ELISA protein standards

The expression of soluble LHCGR (sLHCGR, N-terminal 336 residues of the ECD) as a thioredoxin fusion protein in *Escherichia coli* (*E. coli*) bacteria carrying mutations in both thioredoxin reductase (*TrxB*) and glutathione reductase (*gor*) genes has been reported [21]. This chimeric sLHCGR was shown to have a similar specificity and affinity for hCG as the intact native LHCGR [21]. This protocol was therefore followed in order to produce sLHCGR standard for ELISA assays. Briefly, cDNA encoding the N-terminal 316 amino acid residues of the LHCGR ECD was cloned into the Eco RI (5') and Sal I (3') sites of pET32a(+) vector (Novagen, USA) to generate an *E. coli* bacterial clone. With respect to orientation, the clone contained two histidine repeat tags, one at the C-terminus and the other sandwiched between the LHCGR ECD and TrxB at the N-terminus. The DNA sequence of the insert was confirmed prior to transformation of *E. coli* (Origami strain *trxB gor* (DE3) pLysS (kanR, tetR, CmR), Novagen, USA). The protocol for expression of the LHCGR fusion protein and affinity purification through Ni-NTA resin column (Qiagen) were exactly as described [21]. The estimated relative

molecular mass of the fused sLHCGR was 57541 with pI of 6.15. The affinity purified protein was > 90% pure and the yield varied from 6.63 to 7.34 mg/L. The affinity purified protein was stored at a concentration of 0.255 mg/mL (4.4316 μ M) in 25% glycerol at -20°C.

Unlike sLHCGR standard, the creation of an *in vitro* LH-LHCGR complex standard was less straight forward. Previous work [22] had established that a tethered single chain hCG-LHCGR cloned in baculovirus and expressed in insect cells was functional with respect to ligand-receptor interaction. Moreover, this yoked hCG-LHCGR ECD was shown to be secreted from insect cells at levels 20-fold higher than conventional eukaryotic expression systems [22]. Our goal was to produce a yoked LH β -sLHCGR single chain protein containing the epitopes recognized by both LH β and LHCGR antibodies. Therefore, the open reading frame encoding the entire 141 amino acids of hLH β was synthesized (Source: UniProtKB/Swiss-Prot;Acc:P01229). A linker sequence encoding the hCG β C-terminal peptide (CTP, constituting amino acids 116-145 of hCG β) was ligated at the 3' end of the above construct (hLH β -CTP). The addition of the CTP sequence has been shown to stabilize the expressed fusion protein [22]. A cDNA clone encoding 115 to 291 amino acid residues of the N-terminal end of LHCGR ECD was produced. The hLH β -CTP was ligated to the 5'-end of the modified LHCGR and cloned into p3XFLAG-CMV-14 vector to create an *E. coli* bacterial clone. The hLH β -sLHCGR complex was first expressed in transfected CHO cells and the specificity of the yoked hLH β -sLHCGR protein was established by testing anti-LHCGR, anti-hLH β and anti-FLAG monoclonal antibody binding of the recombinant and mock transfected CHO extracts in plate assays. For large scale production, the protein was expressed in baculovirus transfected sf9 insect cells in order to ensure correct eukaryotic glycosylation of the LH moiety of the fusion protein. Purification was achieved by loading the culture supernatant onto FLAG M2 affinity gel, followed by elution with TBS (50 mM Tris-HCl, 150 mM NaCl, pH 7.4) containing 200 ng/ μ L FLAG peptide (synthetic octapeptide, N-Asp-Tyr-Lys-Asp-Asp-Asp-Lys-C molecular weight 1013.0). The yield of the yoked hLH β -sLHCGR protein was 0.43 mg/L with an estimated purity of 50%. The relative molecular mass of the fusion protein backbone was 40850 (pI 6.65). The molecular mass of glycosylation was not included in quantification calculations. The affinity purified protein was stored at a concentration of 52.5 μ g/mL (1.2851 μ M) in 25% glycerol at -20°C.

ELISA standards were two-fold serially diluted with extensive mixing through 25 mM Bicine (Fluka), 50 mM Tris pH 7.8, 170 mM NaCl in uncoated vinyl mixing plates (Costar, UK) immediately prior to loading onto a pre-coated ELISA plate. The concentration of the first dilution


for each standard was as follows: sLHCGR, 39.88 picomoles per mL; LH-sLHCGR, 20.5616 picomoles per mL.

ELISA procedure

Standard ELISA methods were followed for quantitative analysis of the sLHCGR and LH-LHCGR protein in the serum samples. Details for antibody coating of ninety-six-well plates, antigen binding, antigen detection and data analysis will be published elsewhere (manuscript in preparation).

Human sera and sLHCGR and LH-sLHCGR protein standards show dilution dependent effects in ELISA

The specificity of the capture-detection system for ELISA was first established employing anti-FLAG affinity purified recombinant LHCGR proteins (LHCGR ECD, amino acid residues 1-291) expressed in CHO cells [19]. The estimated purity of this affinity purified LHCGR standard from CHO cell extracts was 40-50%, as judged by SDS-PAGE and western blots. Subsequently, bacterially expressed affinity purified recombinant LHCGR ECD which had a consistent purity of > 90% (see Methods) was used for all sera analyses (Figure 1a). This sLHCGR standard produced a linear dilution dependent response when LHR29 and 5A10C9 were used as capture and detection antibodies, respectively. The sensitivity (limit of detection) of the assay was less than 0.62 pmol/mL (Figure 1b). The dilution dependent linear response of the sLHCGR ELISA system was further established by examining the dilution effect of three early pregnancy sera (Figure 1c). The LH-sLHCGR standard, created by tethering LH to a portion of the LHCGR ECD was expressed in insect cells to preserve glycosylation and the anti-FLAG affinity purified fusion protein was approximately 50% pure (see Methods, Figure 1d). Serially diluted LH-sLHCGR protein was captured by 5A10C9 and was detected by HRP-conjugated anti-LH β monoclonal antibody. Based on the estimated purity of the standard, the sensitivity (limit of detection) of the assay was < 0.64 pmol/mL (Figure 1e). Although the affinity purified LH-sLHCGR standard appeared as three bands on western blot (Figure 1d), it was unclear whether all three were active on ELISA and whether they might be multimers of the protein standard, therefore purity calculations were based solely on the band of expected relative molecular mass (40850). In addition, the contribution of glycosylation to molecular mass was not included in molarity calculations. All measurements for LH-sLHCGR complex are therefore conservative, but consistent for inter-comparison of sera values. The dilution dependent linear response of the LH-sLHCGR ELISA system was further established by examining the dilution effect of sera from three female patients seeking fertility treatment (Figure 1f).



Patients

This prospective study had a broad aim to examine the association of pre-treatment serum sLHCGR and LH-sLHCGR concentrations with treatment outcome for patients seeking fertility treatment at Midland Fertility Services (MFS), Aldridge, UK. This study was approved by West Midlands Research Ethics Committee, UK. Written informed consent was obtained from the participants of this study, with the understanding that consent could be withdrawn by the patient at any time without prejudice.

Statistical analysis

The means, standard deviations, variance (anova), confidence intervals (CI) for each data set were computed using Analysis ToolPak (ATP) software. The significance of differences between groups was evaluated using two-sample paired t-test. ELISA assay standard curves were generated following examination of the natural log plot of the optical density (OD) at 450-620 nm for all the standard points to ensure that the points form a straight line.

The graph plotting and statistical analyses were carried out using the R statistical environment and the ggplot2 package running on a Linux operating system. Correlation testing was performed using the Pearson product moment method which is available in the standard R package. General file manipulations and data cleaning were implemented using the Awk programming language or custom programs written in Python. All software was open source and is freely available from publicly accessible sites.

Results

Clinical samples; regimens, oocyte yields, pregnancy outcomes and data collection

Baseline serum samples (cycle day 2-5) were obtained from 276 women who attended the clinic. Of these, 161 patients enrolled in an IVF or ICSI/IVF cycle. All samples irrespective of fertility treatment, were assayed for FSH, LH, AMH, sLHCGR and LH-sLHCGR; however, AMH together with LH data were not available for seven patients.

One mL follicular fluid samples were obtained during oocyte collection and were stored exactly as serum samples. For patients undergoing fertility treatment, the hormone data (FSH, LH, AMH) in conjunction with information on age, antral follicle count (AFC) and Body Mass Index (BMI) were used to determine the optimum dose for ovarian stimulation assuming a desired oocyte yield of 8-14 mature oocytes. Information on sLHCGR or LH-sLHCGR serum concentration, where known, was not used to alter patient treatment regimens. The majority of patients undertook a 'long-protocol' stimulation regimen with GnRH agonist down-regulation commenced in the luteal phase. Patients with a high baseline FSH level (> 10 IU/L) undertook a 'short protocol' stimulation regimen with GnRH antagonist control. Despite the attempt to 'normalise' the response in terms of oocyte yield, there was a wide variation with respect to the oocyte yield (range 1-39) and as expected there was a strong positive correlation between oocyte yield and AMH levels (see below). Given that there are no absolute cut-off values for 'low' and 'high responders' the patients were divided into three groups: High responders, with ≥ 15 oocytes; intermediate responders with 8-14 oocytes and low responders with a yield of ≤ 7 oocytes; 48.6 to 70.4% of the oocytes were fertilized; $> 95\%$ of the patients had two fresh embryos transferred. Each group was further sub-divided by the pregnancy outcome (*i.e.* pregnant or non-pregnant). In the high response group (54 patients), 17 (31.5%) became pregnant, 14 did not become pregnant and 23 (42.6%) had all their embryos frozen due to a significant risk of OHSS. In the intermediate responder group (54 patients), 27 (50%) became pregnant. In the low response group (53 patients), 13 (24.5%) became pregnant and 40 did not. Pregnancy was initially confirmed by hCG test and by ultrasound scan showing fetus at around 7 wk following transfer.

sLHCGR is detected in follicular fluid, plasma and serum

In a comparative analysis, 8 pairs of pre-treatment serum and follicular fluid (following LH or hCG ovarian stimulation) from 8 patients undergoing fertility treatment were assayed for sLHCGR. Although the mean concentration of sLHCGR was always higher (≥ 1.9 -fold) in the serum compared to the follicular fluid, concentrations in each followed a similar pattern. In some patients sLHCGR was undetectable in both serum and follicular fluid (data not shown). Concentrations of sLHCGR in paired plasma and serum samples from either pregnant or non-pregnant women were generally comparable (data not shown).

Low and high serum AMH are inversely related to pre-treatment LHCGR/LH-LHCGR concentrations

We examined the relative concentrations of serum FSH, sLHCGR and LH-sLHCGR at very low and high AMH

levels. As expected, at very low AMH (0.3-2.2 pmol/L), the FSH concentration was significantly high ($P < 0.001$) with a correlation coefficient of $r = -0.62$ (Figure 2a). Moreover, at these levels of AMH (≤ 4 pmol/L), the average FSH:LH ratio was 2.3:1. At low AMH (≤ 4 pmol/L), the sLHCGR concentrations were relatively high (> 20 pmol/mL) in 35.1% ($^{13}/_{37}$) of patients (Figure 2b) with correlation of $r = -0.25$ ($P = 0.14$). Serum sLHCGR was similarly inversely related ($r = -0.49$, $P = 0.03$) at AMH range of ≥ 45 pmol/L (Figure 2d). In $\sim 70\%$ ($^{16}/_{23}$) of these women, the serum LH-sLHCGR was either undetectable (52.2%) or ≤ 1.0 pmol/mL (17.4%, see below). Moreover, unlike the low AMH group (≤ 4 pmol/L), FSH failed to significantly correlate with AMH (Figure 2c) and the FSH:LH ratio in patients with high AMH (≥ 45 pmol/L) was 1.2:1 (data not shown). Together, these results suggest that low FSH:LH ratio ($\leq 1:1$) and undetectable or low sLHCGR/LH-sLHCGR could be independent indicators of PCO/OHSS.

More than 30% of all patients tested have high serum sLHCGR

To establish the prevalence and concentration range of sLHCGR in women presenting for IVF treatment, early cycle LH and sLHCGR levels were measured and compared in 273 patients. The LH concentrations in 47% (128 patients) and 46% (126 patients) of the samples were 0.07-5.0 IU/L and 5.0-10.0 IU/L, respectively, while the remaining 7% (19 patients) samples had > 10.0 IU/L (Figure 3a). When compared, 52% (141 patients) and 16% (45 patients) of the samples had serum sLHCGR of 0-9.9 pmol/mL and 10-20 pmol/mL, respectively (Figure 3b). The remaining 32% (87 patients) had high concentrations of sLHCGR (> 20 pmol/mL). High levels of early cycle serum LH (≥ 10 IU/l) is usually associated with PCO and susceptibility to heightened ovarian response on controlled ovarian stimulation. Therefore, LH values > 9 IU/L were compared with corresponding sLHCGR levels. This analysis revealed that a negative correlation ($r = -0.397$, $P < 0.05$) exists between concentrations of the hormone and the soluble receptor (Figure 3c).

Age negatively correlates with pre-treatment sLHCGR levels in non-OHSS women

Comparative analysis of AMH with age (range 21 to 47 yrs) on 269 women showed a correlation coefficient of $r = -0.411$, confirming that the women in the higher age group tend to have low AMH and reduced ovarian reserve (data not shown). Based on this observation, we asked whether pre-treatment sLHCGR correlates with patient age. In those that were low responders age had a significant impact on sLHCGR levels (Figure 4a-c). In responders yielding ≤ 7 oocytes age was inversely correlated with sLHCGR serum concentrations ($r = -0.31$, $P = 0.05$, Figure 4a). The age-effect became more evident




Figure 2 High serum FSH and low sLHCGR are inversely related to the pre-treatment serum AMH concentrations. The basal AMH concentrations at ≤ 4 pmol/L and ≥ 45 pmol/L were compared with corresponding FSH (a & c) and sLHCGR (b & d) concentrations. The correlation coefficient (r) and the level of significance (P value) are shown in each case.





Figure 3 A large proportion of women (> 30%) seeking fertility treatment have > 20 pmol/mL, high pre-treatment sLHCGR. The frequency and distribution of the concentrations of a) LH and b) sLHCGR measured in 274 women seeking fertility treatment are shown. Additionally, the LH concentrations ≥ 9.1 IU/L are inversely related to the sLHCGR levels.

among responders producing ≤ 5 ($r = -0.50$, $P < 0.01$) or ≤ 4 ($r = -0.58$, $P = 0.01$) oocytes (Figure 4b and 4c). This suggests that the younger women who exhibit a low response to COS would be more likely to have higher serum sLHCGR than older women with the same oocyte yield. Despite a lack of statistical significance ($P = 0.14$), it is interesting to note that an opposite correlation may exist in the case of high responders (oocytes ≥ 15) who exhibit OHSS; where age tended to be positively correlated ($r = +0.38$) with sLHCGR concentrations (Figure 4d). Although not statistically significant, these results may indicate that older women with high AFC might produce increased sLHCGR.

High pre-treatment serum sLHCGR is negatively associated with oocyte yield

The relative yield of oocytes with respect to pre-treatment sLHCGR was analysed in high (≥ 15 oocytes) and low (< 15 oocytes) responders by estimating the mean pmol/mL



sLHCGR per oocyte. In the high response group, women with OHSS had the lowest amount of mean sLHCGR/oocyte (0.58 pmol/mL), compared to non-pregnant (1.63 pmol/mL) and pregnant (0.77 pmol/mL) women (Figure 5a). Overall, for those who yielded > 15 oocytes, irrespective of pregnancy or OHSS, the average level of sLHCGR per oocyte was 0.99 pmol/mL. However, for those with 5-15 oocytes, both pregnant (5.7 pmol/mL) and non-pregnant women (5.1 pmol/mL), had an average pre-treatment sLHCGR concentration of 5.4 pmol/mL per oocyte (Figure 5b), which is over 5-fold more than those yielding 15 or more oocytes. A similar analysis of the low responders (oocytes ≤ 5) showed an even higher concentration of sLHCGR per oocyte (8.7 pmol/mL/oocyte, Figure 5b). These results may indicate that high pre-treatment sLHCGR serum concentrations could alter functional LH levels leading to an inhibition of the release of oocytes following COS.


High LH-sLHCGR concentrations correspond with poor treatment outcomes in low responders

The results shown above (Figure 5a and 5b) prompted examination of the fraction of sLHCGR bound to the hormone (LH-sLHCGR). The percentage of sLHCGR bound to LH (LH-sLHCGR) with respect to the yield of oocytes was analyzed for women who did not become pregnant (Figure 5c) or who became pregnant (Figure 5d). Of those who produced few oocytes (≤ 7) and who failed to become

pregnant, many had a larger fraction of the serum sLHCGR bound to LH. Indeed, the saturation levels of sLHCGR with LH (expressed as a percentage of sLHCGR/LH-sLHCGR) in those who produced few oocytes (≤ 7) and did not become pregnant were on average similar to those with an intermediate number of oocytes (8-14 oocytes) who did become pregnant (15% versus 14% respectively). Intriguingly, in those with an intermediate number of oocytes (8-14 oocytes) who failed to become pregnant, the average percentage saturation of sLHCGR by LH was just 7%. By contrast, the average percentage saturation of sLHCGR by LH in 12 of 13 women who produced few oocytes (≤ 7) and who did become pregnant was 6%, suggesting that a downward shift in sLHCGR saturation levels may have enabled pregnancy in these low responders. A similar shift in sLHCGR saturation levels was noted in high responders, where those who became pregnant had a lower saturation level (7%) compared to those who failed to become pregnant (11%). Overall, these data suggest that the saturation level of sLHCGR by LH may be an important pregnancy determinant. High pre-treatment LH saturation levels of sLHCGR, coupled with either a low or high oocyte yield following COS, may be a useful indicator of poor treatment outcome.

Low serum sLHCGR/LH-sLHCGR favours embryo implantation in high and low responders


sLHCGR/LH-sLHCGR data for each clinical condition (high, intermediate and low response) in the context of each outcome (with pregnancy, without pregnancy or OHSS) are presented in dot-plots (Figure 6) and summarized in Table 1. Each condition has been represented by two sets of data: with and without cut-off values (open circle and triangle, respectively). To obtain more accurate estimates reflecting $> 90\%$ of the population, outliers were not incorporated in statistical analysis (Figure 6). The mean pre-treatment serum sLHCGR and LH-sLHCGR levels in high (oocytes ≥ 15), intermediate (oocytes, 8-14) and low responders (oocytes ≤ 7) are shown in Figure 6 and in Table 1. In high responders (oocytes ≥ 15), mean sLHCGR (Figure 6a) and LH-sLHCGR (Figure 6c) levels were significantly lower than in women who failed to become pregnant. Similarly, women with OHSS had lower sLHCGR/LH-sLHCGR than the corresponding non-pregnant women (Figure 6a & 6c). Among low responders (oocytes ≤ 7), high sLHCGR/LH-sLHCGR is also significantly associated with a lack of embryo implantation. Levels of sLHCGR/LH-sLHCGR in women with intermediate response (oocytes, 8-14) had little effect on pregnancy outcome (Figure 6b & 6d). However, saturation levels of sLHCGR differed between those who achieved pregnancy and those who did not (Figure 4c and 4d). Together, these results suggest that while high serum sLHCGR/LH-sLHCGR inhibit embryo implantation in high



(oocytes ≥ 15) and low responders (oocytes ≤ 7), women yielding optimum number of oocytes (8-14) are unaffected by their absolute pre-treatment sLHCGR concentrations. As shown in Table 1, women with highest yield of average number of oocytes experiencing OHSS (FAE), had highest serum AMH and lowest mean FSH:LH ratio (0.9 ± 0.3).

Moreover, low responders (oocytes ≤ 7) had highest FSH:LH ratio (1.9 ± 1.4).

Of 23 patients with OHSS, one became pregnant spontaneously, two did not participate in further treatment and for one patient, frozen embryo transfer (FET) is scheduled in the near future. Of the remaining patients (nineteen),



twelve failed to become pregnant and seven were pregnant following FET; five of the seven who became pregnant had pre-treatment sLHCGR below 10 pmol/mL (data not shown).

Discussion

Here we describe the development and use of two ELISA assays that quantitatively measure sLHCGR and sLHCGR in complex with LH (LH-sLHCGR) in human

Table 1 A summary of the mean serum hormone concentrations (AMH, LH and FSH, FSH:LH ratio), receptor (sLHCGR) and LH-LHCGR concentrations and the number of oocytes with respect to the fertility treatment outcome

Hormones Receptors	Oocytes ≥ 15 Not Pregnant N = 13	Oocytes ≥ 15 Pregnant N = 16	Oocytes ≥ 15 OHSS; FAE N = 22	Oocytes ≤ 7 Not Pregnant N = 38	Oocytes ≤ 7 Pregnant N = 11	Oocytes 8-14 Not Pregnant N = 23	Oocytes 8-14 Pregnant N = 25
Number of oocytes	16.9(± 1.1)	17.1(± 0.8)	24.4 (± 0.3)	4.2 (± 0.6)	5.0 (± 1.0)	10.9 (± 0.6)	9.8 (± 0.7)
AMH, pmol/L	19.3(± 5.2)	18.3(± 4.1)	46.6 (± 9.9)	10.1 (± 3.2)	5.6 (± 2.6)	13.3 (± 3.7)	12.9 (± 3.6)
sLHCGR, pmol/mL	14.3(± 7.7)	7.9 (± 3.8)	9.9 (± 4.2)	16.2 (± 6.7)	6.9 (± 4.6)	19.5 (± 17.9)	15.2 (± 7.5)
LH-LHCGR, pmol/mL	1.35(± 1.0)	0.53(± 0.4)	0.88 (± 0.6)	2.98 (± 2.1)	1.4 (± 1.0)	3.0 (± 3.67)	2.48 (± 1.6)
LH, IU/L	5.9 (± 1.0)	4.5 (± 0.9)	7.3 (± 2.7)	5.9 (± 1.2)	5.1 (± 1.1)	4.9 (± 0.7)	5.2 (± 0.8)
FSH, IU/L	6.5 (± 0.7)	6.7 (± 1.0)	6.3 (± 0.9)	9.0 (± 1.3)	9.7 (± 1.6)	7.0 (± 0.7)	7.7 (± 0.9)
FSH/LH	1.1 (± 0.7)	1.5 (± 1.1)	0.9 (± 0.3)	1.5 (± 1.0)	1.9 (± 1.4)	1.4 (± 1.0)	1.5 (± 1.1)

No Pregnancy, Pregnancy and OHSS shown in Figure 6. The numbers in parentheses are confidence intervals (± CI).

serum from women seeking fertility treatment. In addition to serum, these ELISA assays could quantitatively measure sLHCGR and LH-sLHCGR in human plasma and follicular fluids.

Serum AMH is increasingly used in fertility treatment as an indicator of ovarian reserve. Very low (0-4 pmol/L) and very high (≥ 45 pmol/L) AMH concentrations are associated with reduced oocyte yields and PCO (risk of OHSS) following COS, respectively [8]. Our data demonstrate the expected correlation between AMH levels and oocyte yield in women who exhibited OHSS and had all embryos frozen. However, high AMH (> 39 pmol/L) was a positive predictor for only 52% (12/23) of these patients; the remaining 48% (11/23) had AMH values ranging from 7.6-35 pmol/L. Regarding pregnancy, like many other reports [23-26], we found no correlation between AMH and the embryo implantation potential. We have described three categories of patients seeking fertility treatment with respect to the basal (pre-treatment) serum concentrations of sLHCGR/LH-sLHCGR: undetectable to very low (low), intermediate (optimal) and very high. Patients who were high (oocytes ≥ 15) and low responders (oocytes ≤ 7), had fresh transfers and became pregnant had soluble receptor levels that were significantly lower than those who did not become pregnant. Comparing pregnancy rates in low and high responders we found that the levels of LH complexed with sLHCGR were low in those who became pregnant (low and high responders) and higher in those who did not become pregnant. Although embryos were not transferred, the OHSS group (oocytes ≥ 15) also had low sLHCGR/LH-sLHCGR and FSH:LH ratio. A comparison of pregnancy rates among those producing an intermediate number of oocytes (8-14) revealed the opposite; those who became pregnant had higher levels of LH complexed to sLHCGR than did those who did not become pregnant. The results for complexed LH-sLHCGR amongst intermediate responders were not considered statistically significant and would require a larger study to verify a significant difference. Nevertheless, we believe that this observation merits discussion because, if verified, it could indicate that an optimum saturation level of sLHCGR that correlates with oocyte yields, is important for pregnancy. Moreover, if verified, this result might suggest an important biological function for sLHCGR in modulating LH availability, e.g. by acting as an LH reservoir as observed for IL-4 and growth hormone and tumor necrosis factor receptors [27-30]

Given that the production of soluble polypeptide hormone and cytokine receptors is regulated by alternative splicing, protease activation, secretion of membrane vesicles [31], ligand-mediated receptor activation [15] and stress [19], the higher concentrations of the sLHCGR/LH-sLHCGR that we have observed could be attributed to

infection, endometriosis, ovarian and adrenal pathology, obesity, insulin resistance and other metabolic diseases. Notably, a recent report suggests hCG stimulates LHCGR expression in lymphocyte during controlled ovarian stimulation and is linked to improved implantation [32]. On the other hand, undetectable to low circulating sLHCGR/LH-sLHCGR might reflect reduced hormonal activation and down regulation of sLHCGR synthesis as observed in Down's syndrome placenta [33,34]. This may suggest that like other cytokine and hormone receptors [27-30], the production of sLHCGR is regulated.

What could be the patho-physiological significance of sLHCGR in the context of COS and implantation of the embryo? There are two possible mutually non-exclusive ways the sLHCGR could affect the LH/hCG functions: sLHCGR is intrinsically a specific serum binding protein [28-30] which stabilizes or prevents degradation of the LH/hCG until the hormone is delivered to the traditional membrane-bound receptor. In extreme conditions (low or undetectable sLHCGR), leading to OHSS and high response might reflect an unregulated burst of stimulation resulting from hormonal induction. This is consistent with fast and slow disappearance (double exponential curves) of LH and hCG reported a few decades ago [35]. Accordingly, very short serum half-life of variably glycosylated LH (20-80 min, [35,36]) compared to FSH (several hrs, [37]) and hCG (1-3 days, [38]) suggests that combined and sustained LH-FSH induction of ovarian functions would require receptor-mediated stabilization, specifically of LH enhancing its resistance to clearance. Therefore, in addition to OHSS, our data demonstrate the increased release of oocytes (≥ 15) on COS is associated with low sLHCGR/LH-sLHCGR concentrations (Figure 5 and Table 1). The possibility that an optimal level of sLHCGR complexed with LH exists that promotes pregnancy in those producing 8-14 oocytes might support a physiological reservoir role for sLHCGR in regulating LH availability. In an alternative scenario [27,39,40] the mobile sLHCGR may compete with membrane-associated counterparts for binding to circulating LH/hCG. Therefore, increased levels of serum sLHCGR modulate the LH/hCG activity by inhibiting their interactions with cell surface receptors. In general, high serum sLHCGR concentrations are linked to reduced production of oocytes as well as poor implantation (Figures 5, 6 and Table 1). This could be again linked to the inhibitory effect of circulating sLHCGR on LH/hCG functions.

Pre-treatment serum sLHCGR/LH-sLHCGR and LH levels could provide an indication of functional LH levels that would allow the adjustment of hormone dose prior to ovarian induction. This could be an important step towards avoidance of OHSS, particularly for patients whose AMH levels do not correlate with high oocyte yield and potential OHSS. It should be emphasized that we

have measured baseline, pre-treatment sLHCGR concentrations and that during fertility treatment and prior to embryo transfer, these concentrations could alter. Indeed, this might explain both positive and failed implantation when the pre-treatment serum LH receptor concentrations in some women were high and low, respectively (Figure 6). Therefore, the true effect of circulating sLHCGR in modulating implantation and early pregnancy would require its estimation before and immediately after embryo transfer. Future experiments are needed to test this hypothesis.

Critical clinical parameters that predict reduced response to COS are age, BMI, early cycle FSH, LH, inhibin B, antral follicle counts (AFC) and AMH concentrations [5,41]. Of these, serum AMH and AFC are recognized as superior predictors of ovarian reserve and OHSS [8]. Our study indicates that in the absence of AMH data, measurement of pre-treatment circulating sLHCGR/LH-sLHCGR together with FSH:LH ratios, age and AFC might provide sufficient information on aberrant ovarian response to establish individualized hormone combinations, daily doses and duration of treatment prior to COS.

The improvement of pregnancy outcome could be another potential benefit of measuring pre-treatment serum sLHCGR. Following a decline in LH support, hCG is the foremost leutotropic paracrine signal produced by the embryo, well before the implantation begins [7]. This hCG signaling critically influences the blastocyst development, uterine receptivity through stromal fibroblast proliferation, secretion of IGF binding protein-1, NK cell activation and apoptosis (Fas-FasL), transient immune tolerance through activation of regulatory T-cells and dendritic cells (MHC class II, IL-10 and IDO expression), and endometrial angiogenesis through secretion of VEGF [42,43]. Furthermore, an increased LH surge is associated with a high rate of miscarriage [44]. Therefore, measurement of sLHCGR/LH-sLHCGR following embryo transfer together with targeted hCG therapy could improve pregnancy outcome by extending the window of implantation and simultaneously reducing the frequency of miscarriage.

The bioactive serum/plasma LH concentrations, conventionally measured by Leydig cell assay [45] have been shown to be significantly lower than the immunoreactive hormone in various clinical conditions affecting ovarian functions and fertility [46,47]. Whether the ELISA assays described here for measuring the soluble LH receptor and the hormone-receptor complex would be comparable to the Leydig cell assay with respect to LH bioactivity requires a separate investigation. The link between hypogonadism and LHCGR functions was first demonstrated by partial purification of M_r 30 K-60 K serum proteins that were found to competitively inhibit the hormone binding to the LH receptor and affect testosterone production in uremic boys [48].

Conclusions

Two hormones, LH and hCG use a common cell-surface receptor, known as LHCGR, to transmit signals into cells. Although this receptor is normally tethered to the surface of a cell, new variants (sLHCGR) have been found circulating in the blood. These variants do not transmit signals but may potentiate or inhibit LH and hCG functions. Our group has developed novel assays to measure the level of sLHCGR and LH-sLHCGR complex in women seeking IVF treatment. It was found that those who produced a few oocytes (less than 7) or many oocytes (more than 15), had low concentrations of sLHCGR and a good IVF outcome (i.e. pregnancy), whereas a high level of sLHCGR within these two groups was indicative of a poor IVF outcome (i.e. not pregnant). For those producing an intermediate number of oocytes (8-14) the levels of sLHCGR did not appear to affect pregnancy. These new tests could be useful in avoiding ovarian hyperstimulation and may help circumvent a situation where all embryos need to be frozen. Moreover, if used before uterine transfer of the embryo, these assays may also identify those women who may benefit from short-term supplementation with hCG in order to firmly establish the pregnancy.

Acknowledgements

This study would not have been possible without the understanding, enthusiasm and consent of the patients who provided the serum samples prior to their fertility treatment. We would like to thank Dr Alan Jones for providing the laboratory facilities to conduct this research at Heartlands Hospital. We are grateful to Dr Geeta Nargund for providing follicular fluid, to Dr Michael Christiansen for providing paired plasma and serum samples from first trimester gestation and to Dr Harpal Randeva for providing plasma samples from metformin/pioglitazone treated women. These samples were used to test the sLHCGR ELISA system during development. SB appreciates an inspiring discussion with Dr Robert Edwards on the concept of a soluble LH receptor at a meeting in London. This work was supported in part by grants from Advantage proof of concepts (APOC) and Advantage West Midlands (AWM). Finally, we would like to thank all reviewers for comments and suggestions that improved the presentation of this manuscript.

Author details

¹Department of Clinical Biochemistry, Heartlands Hospital, Birmingham B9 5SS, UK. ²Midland Fertility Services, Aldridge WS9 8LT, UK. ³Origin Biomarkers, BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire, AL7 3AX, UK.

Authors' contributions

AEC developed the ELISA system, performed all ELISAs, analysed the data, contributed to the interpretation of results, creation of manuscript figures and first draft of the manuscript. KPN collected the patient sera, collated all clinical data and contributed to interpretation of the results. WEM performed statistical analysis on the data and contributed to the creation of manuscript figures. GML presided over the clinical aspect of the study and contributed to the interpretation of results. SB conceived and initiated the study, designed the standards and monoclonal antibodies used in the ELISAs, presided over the statistical analyses, interpretation of results, creation of manuscript figures and the first draft of the manuscript. All authors read and approved the final manuscript.

Competing interests

The use of sLHCGR-based immunodiagnostic tests has been patented.

Received: 1 November 2011 Accepted: 23 December 2011
Published: 23 December 2011

References

- Edwards RG: Widening perspectives of intracytoplasmic sperm injection. *Nat Med* 1999.
- Daya S: Luteal support: progestogens for pregnancy protection. *Maturitas* 2009, **1(65 Suppl)**:S29-S34.
- Chiazze L Jr, Brayer FT, Macisco J Jr, Parker MP, Duffy BJ: The length and variability of the human menstrual cycle. *JAMA* 1968, **203(6)**:377-380.
- Lainas T, Zorzovilis J, Petsas G, Stavropoulou G, Cazlaris H, Daskalaki V, Lainas G, Alexopoulou E: In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF. *Hum Reprod* 2005, **20(9)**:2426-2433.
- Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, Mitchell P, Ambrose P, Fleming R: Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. *Hum Reprod* 2009, **24(4)**:867-875.
- Johnson SR, Miro F, Barrett S, Ellis JE: Levels of urinary human chorionic gonadotrophin (hCG) following conception and variability of menstrual cycle length in a cohort of women attempting to conceive. *Curr Med Res Opin* 2009, **25(3)**:741-748.
- Chen SU, Chen RJ, Shieh JY, Chou CH, Lin CW, Lu HF, Yang YS: Human chorionic gonadotropin up-regulates expression of myeloid cell leukemia-1 protein in human granulosa-lutein cells: implication of corpus luteum rescue and ovarian hyperstimulation syndrome. *J Clin Endocrinol Metab* 2010, **95(8)**:3982-3992.
- La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Arsenio AC, Stabile G, Volpe A: Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). *Hum Reprod Update* 2010, **16(2)**:113-130.
- Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP: Anti-Müllerian hormone as a predictor of IVF outcome. *Reprod Biomed Online* 2007, **14(5)**:602-610.
- Li HWR, Yeung WSB, Lau EYL, Ho PC, Ng EHY: Evaluating the performance of serum antimüllerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine insemination. *Fertil Steril* 2010, **94(6)**:2177-2181.
- Chambers AE, Banerjee S: Natural antisense LHCGR could make sense of hypogonadism, male-limited precocious puberty and pre-eclampsia. *Mol Cell Endocrinol* 2005, **241(1-2)**:1-9.
- Filicori M, Fazleabas AT, Huhtaniemi I, Licht P, Rao CV, Tesarik J, Zygmunt M: Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management of infertility. *Fertil Steril* 2005, **84(2)**:275-284.
- Rahman NA, Rao CV: Recent progress in luteinizing hormone/human chorionic gonadotropin hormone research. *Mol Hum Reprod* 2009, **15(11)**:703-711.
- Kolena J, Seböková E: Porcine follicular fluid containing water-soluble LH/hCG receptor. *Arch Int Physiol Biochim* 1986, **94(4)**:261-270.
- West AP, Cooke BA: Regulation of the truncation of luteinizing hormone receptors at the plasma membrane is different in rat and mouse Leydig cells. *Endocrinology* 1991, **128**:363-370.
- Tsai-Morris CH, Buczko E, Wang W, Dufau ML: Intronic nature of the rat luteinizing hormone receptor gene defines a soluble receptor subspecies with hormone binding activity. *J Biol Chem* 1990, **265(32)**:19385-19388.
- VuHai-LuuThi MT, Misrahi M, Houllier A, Jolivet A, Milgrom E: Variant forms of the pig lutropin/choriogonadotropin receptor. *Biochemistry* 1992, **31(35)**:8377-8383.
- Remy JJ, Nespoulous C, Grosclaude J, Grébert D, Couture L, Pajot E, Salesses R: Purification and structural analysis of a soluble human choriongonadotropin hormone-receptor complex. *J Biol Chem* 2001, **276(3)**:1681-1687.
- Chambers AE, Stanley PF, Randeava H, Banerjee S: Microvesicle-mediated release of soluble LH/hCG receptor (LHCGR) from transfected cells and placenta explants. *Reprod Biol Endocrinol* 2011, **9**:64.
- Meduri G, Charnaux N, Loosfelt H, Jolivet A, Spyrtos F, Brailly S, Milgrom E: Luteinizing hormone/human chorionic gonadotropin receptors in breast cancer. *Cancer Res* 1997, **57(5)**:857-864.
- Lobel LI, Pollak S, Klein J, Lustbader JW: High-level bacterial expression of a natively folded, soluble extracellular domain fusion protein of the human luteinizing hormone/chorionic gonadotropin receptor in the cytoplasm of *Escherichia coli*. *Endocrine* 2001, **14(2)**:205-212.
- Fralish GB, Narayan P, Puett D: High-level expression of a functional single-chain human chorionic gonadotropin-luteinizing hormone receptor ectodomain complex in insect cells. *Endocrinology* 2001, **142(4)**:1517-1524.
- Tremellen K, Kolo M: Serum anti-Müllerian hormone is a useful measure of quantitative ovarian reserve but does not predict the chances of live-birth pregnancy. *Aust N Z J Obstet Gynaecol* 2010, **50(6)**:568-572.
- Kaya C, Pabuccu R, Satiroglu H: Serum anti-Müllerian hormone concentrations on day 3 of the *in vitro* fertilization stimulation cycle are predictive of the fertilization, implantation, and pregnancy in polycystic ovary syndrome patients undergoing assisted reproduction. *Fertil Steril* 2010, **94(6)**:2202-2207.
- Lamazou F, Genro V, Fuchs F, Grynberg M, Gallot V, Achour-Frydman N, Fanchin R, Frydman R: [Serum AMH level is not a predictive value for IVF in modified natural cycle: analysis of 342 cycles]. *J Gynecol Obstet Biol Reprod (Paris)* 2011, **40(3)**:205-210.
- Weghofer A, Dietrich W, Barad DH, Gleicher N: Live birth chances in women with extremely low-serum anti-Müllerian hormone levels. *Hum Reprod* 2011, **26(7)**:1905-1909.
- Heaney ML, Golde DW: Soluble receptors in human disease. *J Leukoc Biol* 1998, **64**:135-46.
- Baumann G, Stolar MW, Amburn K, Barsano CP, DeVries BC: A specific growth hormone-binding protein in human plasma: initial characterization. *J Clin Endocrinol Metab* 1986, **62**:134-141.
- Herington AC, Ymer S, Stevenson J: Identification and characterization of specific binding proteins for growth hormone in normal human sera. *J Clin Invest* 1986, **77(6)**:1817-1823.
- Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D: Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. *J Exp Med* 1992, **175(2)**:323-329.
- Levine SJ: Molecular mechanisms of soluble cytokine receptor generation. *J Biol Chem* 2008, **283(21)**:14177-14181.
- Drakakis P, Loutradis D, Beloukas A, Sypsa V, Anastasiadou V, Kalofolias G, Arabatzi H, Kiapekou E, Stefanidis K, Paraskevis D, Makrigiannakis A, Hatzakis A, Antsaklis A: Early hCG addition to rFSH for ovarian stimulation in IVF provides better results and the cDNA copies of the hCG receptor may be an indicator of successful stimulation. *Reprod Biol Endocrinol* 2009, **7**:110.
- Banerjee S, Smallwood A, Chambers AE, Papageorghiou A, Loosfelt H, Spencer K, Campbell S, Nicolaidis K: A link between high serum levels of human chorionic gonadotropin and chorionic expression of its mature functional receptor (LHCGR) in Down's syndrome pregnancies. *Reprod Biol Endocrinol* 2005, **3**:25.
- Pidoux G, Gerbaud P, Marpeau O, Guibourdenche J, Ferreira F, Badet J, Evain-Brion D, Frendo JL: Human placental development is impaired by abnormal human chorionic gonadotropin signaling in trisomy 21 pregnancies. *Endocrinology* 2007, **148(11)**:5403-5413.
- Yen SC, Llerena LA, Pearson OH, Littell AS: Disappearance rates of endogenous follicle-stimulating hormone in serum following surgical hypophysectomy in man. *J Clin Endocrinol Metab* 1970, **30(3)**:325-329.
- Kohler PO, Ross GT, Odell WD: Metabolic clearance and production rates of human luteinizing hormone in pre- and postmenopausal women. *J Clin Invest* 1968, **47**:38-47.
- Wide L, Eriksson K, Sluss PM, Hall JE: Serum half-life of pituitary gonadotropins is decreased by sulfonation and increased by sialylation in women. *J Clin Endocrinol Metab* 2009, **94(3)**:958-964.
- Toner GC, Geller NL, Tan C, Nisselbaum J, Bosl GJ: Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. *Cancer Res* 1990, **50(18)**:5904-5910.
- Alcami A, Smith GL: A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. *Cell* 1992, **71**:153-167.
- Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, Lammoglia R, Charnock-Jones DS: A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. *Biol Reprod* 1998, **59(6)**:1540-1548.

41. Lockwood GM, Muttukrishna S, Groome NP, Knight PG, Ledger WL: **Circulating inhibins and activin A during GnRH-analogue down-regulation and ovarian hyperstimulation with recombinant FSH for in-vitro fertilization-embryo transfer.** *Clin Endocrinol (Oxf)* 1996, **45(6)**:741-748.
42. Berndt S, Perrier d'Hauterive S, Blacher S, Péqueux C, Lorquet S, Munaut C, Applanat M, Hervé MA, Lamandé N, Corvol P, van den Brûle F, Frankenne F, Poutanen M, Huhtaniemi I, Geenen V, Noël A, Foidart JM: **Angiogenic activity of human chorionic gonadotropin through LH receptor activation on endothelial and epithelial cells of the endometrium.** *FASEB J* 2006, **20(14)**:2630-2632.
43. Tsampalas M, Grیدهlet V, Berndt S, Foidart JM, Geenen V, Perrier d'Hauterive S: **Human chorionic gonadotropin: a hormone with immunological and angiogenic properties.** *J Reprod Immunol* 2010, **85**:93-98.
44. Regan L, Owen EJ, Jacobs HS: **Hypersecretion of luteinising hormone, infertility, and miscarriage.** *Lancet* 1990, **336(8724)**:1141-1144.
45. Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD: **Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.** *J Clin Endocrinol Metab* 1991, **73(4)**:811-817.
46. Galeraud-Denis I, Bouchard P, Herlicoviez M, Marie E, Carreau S: **Inhibitory effect of plasma obtained from hypophysectomized and control women on the assay of bioactive luteinizing hormone.** *Hum Reprod* 1999, **14(2)**:312-317.
47. Ding YQ, Huhtaniemi I: **Human serum LH inhibitor(s): behaviour and contribution to in vitro bioassay of LH using dispersed mouse Leydig cells.** *Acta Endocrinol (Copenh)* 1989, **121**:46-54.
48. Dunkel L, Raivio T, Laine J, Holmberg C: **Circulating luteinizing hormone receptor inhibitor(s) in boys with chronic renal failure.** *Kidney Int* 1997, **51(3)**:777-784.

doi:10.1186/1477-7827-9-161

Cite this article as: Chambers *et al.*: Circulating LH/hCG receptor (LHCGR) may identify pre-treatment IVF patients at risk of OHSS and poor implantation. *Reproductive Biology and Endocrinology* 2011 **9**:161.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

